Managing Adverse Events: Ponatinib & Asciminib in CML: Expert Approaches

Panelists discuss how clinicians should implement regular cardiovascular monitoring and dose modifications for ponatinib-associated toxicities while being vigilant for asciminib’s key adverse events, including thrombocytopenia, pancreatic dysfunction, and hypertension, with appropriate dose adjustments and supportive care as needed.